193 results
P
Hepatocellular carcinomas (HCCs), non-HCC malignancies
I/C
Contrast-enhanced ultrasound (CEUS) Liver Imaging Reporting and Data System category M (LR-M), CEUS LR-M category, Non-HCC malignancies
O
Proportion of CEUS LR-M in HCC and non-HCC malignancies, Frequency of individual CEUS LR-M imaging features
P
patients with liver lesions
I/C
LI-RADS algorithm, original studies reporting probability of LR-M for HCC and non-HCC malignancy on MRI
O
pooled percentages of HCC and non-HCC malignancy for LR-M, sources of heterogeneity between reported results
P
12,600 participants
I/C
checkpoint inhibitor pneumonitis (CIP), endocrine and skin irAEs, severe-grade irAEs, low-grade irAEs, multiple irAEs, 1 irAE
O
overall survival (OS), objective response rate (ORR)
P
advanced melanoma patients
I/C
immune checkpoint inhibitors (ICIs), ipilimumab, nivolumab, pembrolizumab, chemotherapy drugs (eg, dacarbazine, carboplatin, and paclitaxel)
O
cumulative incidence of any irAEs (regardless of severity), severe irAEs (grades 3-5)
P
TNBC, metastatic TNBC, early TNBC
I/C
ICI, immune checkpoint inhibitors, different ICI agents
O
progression-free survival (PFS), overall survival (OS), pathologic complete response rate (pCR), grade ≥ 3 treatment-related adverse events (trAEs), immune-related adverse events (irAEs), grade ≥ 3 irAEs
P
rodents
I/C
unmodified MSC(M), controls
O
mortality rate
P
cancer patients
I/C
immune checkpoint inhibitors (ICIs), no immune checkpoint inhibitors
O
immune-related adverse events (irAEs)
P
patients with cancer
I/C
neoadjuvant combination immunotherapy, standard of care
O
incidence of immune-related adverse events (irAEs)
P
HIV-infected adults with tuberculosis
I/C
Mycobacterium tuberculosis bloodstream infection (BSI), Patients with HIV-associated tuberculosis but without M. tuberculosis BSI
O
Mortality within 30 days
P
adults with breast cancer
I/C
immune checkpoint inhibitors (ICIs), other conventional therapies
O
any-grade and grade 3-5 adverse events (AEs) and immune-related AEs (irAEs)